Published in Clin Gastroenterol Hepatol on July 23, 2009
The current prevalence of irritable bowel syndrome in Asia. J Neurogastroenterol Motil (2010) 1.74
Validation of symptom-based diagnostic criteria for irritable bowel syndrome: a critical review. Am J Gastroenterol (2010) 1.23
Functional dyspepsia. Therap Adv Gastroenterol (2010) 1.17
Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol (2011) 1.15
The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci (2012) 1.15
Irritable bowel syndrome. Nat Rev Dis Prim (2016) 1.14
Irritable Bowel Syndrome and Co-morbid Gastrointestinal and Extra-gastrointestinal Functional Syndromes. J Neurogastroenterol Motil (2010) 1.01
Diagnosis, comorbidities, and management of irritable bowel syndrome in patients in a large health maintenance organization. Clin Gastroenterol Hepatol (2011) 1.01
Overlap syndrome of functional dyspepsia and irritable bowel syndrome - are both diseases mutually exclusive? J Neurogastroenterol Motil (2011) 0.99
Psychiatric, somatic and other functional gastrointestinal disorders in patients with irritable bowel syndrome at a tertiary care center. J Neurogastroenterol Motil (2012) 0.99
Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver (2011) 0.99
Overlap in patients with dyspepsia/functional dyspepsia. J Neurogastroenterol Motil (2014) 0.94
Excess comorbidity prevalence and cost associated with functional dyspepsia in an employed population. Dig Dis Sci (2011) 0.89
Common Mechanism of Pathogenesis in Gastrointestinal Diseases Implied by Consistent Efficacy of Single Chinese Medicine Formula: A PRISMA-Compliant Systematic Review and Meta-Analysis. Medicine (Baltimore) (2015) 0.88
Irritable bowel syndrome and migraine: bystanders or partners? J Neurogastroenterol Motil (2013) 0.87
Classification of functional dyspepsia based on concomitant bowel symptoms. Neurogastroenterol Motil (2012) 0.86
Anxiety and Depression Increase in a Stepwise Manner in Parallel With Multiple FGIDs and Symptom Severity and Frequency. Am J Gastroenterol (2015) 0.80
Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents. Therap Adv Gastroenterol (2011) 0.80
Reduction in duodenal endocrine cells in irritable bowel syndrome is associated with stem cell abnormalities. World J Gastroenterol (2015) 0.79
Inflammation in irritable bowel syndrome: Myth or new treatment target? World J Gastroenterol (2016) 0.79
Symptom burden and consulting behavior in patients with overlapping functional disorders in the US population. United European Gastroenterol J (2015) 0.78
Sero-prevalence and associated factors of Helicobacter pylori infection among adult patients with dyspepsia attending the gastroenterology unit in a tertiary hospital in Mwanza, Tanzania. Afr Health Sci (2016) 0.77
Stomach antral endocrine cells in patients with irritable bowel syndrome. Int J Mol Med (2014) 0.76
Increased proton pump inhibitor and NSAID exposure in irritable bowel syndrome: results from a case-control study. BMC Gastroenterol (2012) 0.76
Linaclotide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome. Ther Adv Chronic Dis (2013) 0.76
Prevalence of Irritable Bowel Syndrome (IBS), Migraine and Co-Existing IBS-Migraine in Medical Students. J Clin Diagn Res (2016) 0.75
The Effect of Peripheral CRF Peptide and Water Avoidance Stress on Colonic and Gastric Transit in Guinea Pigs. Yonsei Med J (2017) 0.75
Functional Gastrointestinal Disorders in Young Military Men. Gut Liver (2015) 0.75
Gastric Contraction Imaging System Using a 3-D Endoscope. IEEE J Transl Eng Health Med (2014) 0.75
Clinical and Histologic Mimickers of Celiac Disease. Clin Transl Gastroenterol (2017) 0.75
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut (2013) 4.29
Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol (2007) 4.14
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ (2008) 4.12
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 3.97
Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology (2010) 3.32
Effect of comorbidity on mortality in patients with peptic ulcer bleeding: systematic review and meta-analysis. Am J Gastroenterol (2013) 2.97
Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA (2008) 2.89
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol (2005) 2.56
Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev (2013) 2.53
Management of Barrett's esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. Am J Gastroenterol (2008) 2.52
Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev (2010) 2.47
Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology (2006) 2.46
American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology (2005) 2.39
Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol (2005) 2.36
Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut (2010) 2.21
Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology (2013) 2.13
Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology (2005) 2.07
Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 2.04
Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol (2008) 2.02
Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med (2013) 2.01
Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol (2007) 2.00
EUS: a meta-analysis of test performance in suspected choledocholithiasis. Gastrointest Endosc (2008) 1.85
Ulcerative colitis. BMJ (2013) 1.76
Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol (2009) 1.67
Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.60
Symptom-based outcome measures for dyspepsia and GERD trials: a systematic review. Am J Gastroenterol (2005) 1.59
Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study. Gastroenterology (2010) 1.58
Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev (2015) 1.58
Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev (2007) 1.57
Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst (2004) 1.54
Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med (2009) 1.53
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol (2010) 1.50
Inconsistent definitions for intention-to-treat in relation to missing outcome data: systematic review of the methods literature. PLoS One (2012) 1.48
Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol (2004) 1.47
Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol (2008) 1.44
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol (2011) 1.42
Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol (2013) 1.41
Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol (2005) 1.40
Acid-suppressive therapy with esomeprazole for relief of unexplained chest pain in primary care: a randomized, double-blind, placebo-controlled trial. Am J Gastroenterol (2012) 1.40
Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol (2009) 1.39
Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology (2002) 1.36
Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol (2009) 1.29
Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am J Epidemiol (2005) 1.28
Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 1.24
Canadian Helicobacter Study Group Consensus Conference: Update on the approach to Helicobacter pylori infection in children and adolescents--an evidence-based evaluation. Can J Gastroenterol (2005) 1.17
Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.14
How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol (2003) 1.12
Who consults with dyspepsia? Results from a longitudinal 10-yr follow-up study. Am J Gastroenterol (2007) 1.11
Functional Dyspepsia Treatment Trial (FDTT): a double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics. Contemp Clin Trials (2012) 1.10
Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.10
What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol (2010) 1.10
Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study. Gut (2006) 1.08
Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment. Can J Gastroenterol (2007) 1.07
Rates of upper gastrointestinal endoscopy and gastro-oesophageal malignancy outcomes. Gut (2013) 1.05
Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol (2008) 1.04
A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial. Gastroenterology (2005) 1.02
Effect of dyspepsia on survival: a longitudinal 10-year follow-up study. Am J Gastroenterol (2012) 1.02
Peripheral mechanisms in irritable bowel syndrome. N Engl J Med (2013) 1.01
Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol (2008) 0.97
Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol (2011) 0.96
Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn? Am J Gastroenterol (2009) 0.95
Randomized controlled trial comparing telephone and mail follow-up for recruitment of participants into a clinical trial of colorectal cancer screening. Trials (2013) 0.93
Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis. Am J Gastroenterol (2011) 0.93
Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with clostridium difficile: antibiotics alone or combined antibiotics/immunomodulators? Inflamm Bowel Dis (2010) 0.93
Does long term aspirin prevent cancer? BMJ (2010) 0.91
Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey. Scand J Gastroenterol (2015) 0.89
Stress ulcer prophylaxis in critically ill patients: review of the evidence. Pol Arch Med Wewn (2012) 0.89
A systematic review of psychological therapies for nonulcer dyspepsia. Am J Gastroenterol (2004) 0.89
Methodology for randomized trials of patients with nonvariceal upper gastrointestinal bleeding: recommendations from an international consensus conference. Am J Gastroenterol (2009) 0.89
Effect of sibling number in the household and birth order on prevalence of Helicobacter pylori: a cross-sectional study. Int J Epidemiol (2007) 0.87
Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol (2002) 0.86
Guidewire-assisted cannulation of the common bile duct for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. Cochrane Database Syst Rev (2012) 0.85
Addendum: BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am J Gastroenterol (2015) 0.84
WITHDRAWN: Initial management strategies for dyspepsia. Cochrane Database Syst Rev (2009) 0.84
Effectiveness of disseminating consensus management recommendations for ulcer bleeding: a cluster randomized trial. CMAJ (2013) 0.84
Managing dyspepsia. Curr Gastroenterol Rep (2009) 0.83
Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome. Am J Gastroenterol (2009) 0.83
Hip fracture and proton pump inhibitor therapy: position statement. Can J Gastroenterol (2008) 0.83
Eradicating H pylori. BMJ (2004) 0.83
Colorectal cancer screening with fecal occult blood testing (FOBT): an international perspective. Am J Gastroenterol (2006) 0.83
Proton pump inhibitors and risk of bone fractures. Curr Treat Options Gastroenterol (2014) 0.82
Current guidelines for dyspepsia management. Dig Dis (2008) 0.82
Redundant data in the meta-analysis on Helicobacter pylori eradication. Ann Intern Med (2009) 0.82
Phase II randomized trial of carboplatin and gemcitabine with or without dexamethasone pre-treatment in patients with Stage IV non-small cell lung cancer. Cancer Chemother Pharmacol (2013) 0.81
Non-erosive reflux disease--defining the entity and delineating the management. Digestion (2008) 0.80
WITHDRAWN: Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev (2010) 0.80
Barrett's esophagus and obesity: the missing part of the puzzle. Am J Gastroenterol (2008) 0.80
A validation study of the Italian Short-Form Leeds Dyspepsia Questionnaire. Intern Emerg Med (2010) 0.79
Proton pump inhibitors and clopidogrel - hazardous drug interaction or hazardous interpretation of data? Can J Gastroenterol (2009) 0.78
Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum (2009) 0.78
The promises and perils of nurse-led flexible sigmoidoscopy screening. Can J Gastroenterol (2007) 0.78
A second-order simulation model of the cost-effectiveness of managing dyspepsia in the United States. Med Decis Making (2007) 0.78
Is it safe to use a proton pump inhibitor with clopidogrel? Pol Arch Med Wewn (2009) 0.78